Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?

Impact · against what's priced in

The news regarding Regenxbio is moderately positive but reflects a high degree of analyst disagreement. While upward earnings revisions and high price targets suggest growth potential, the significant variance in estimates implies the market is still debating the company's fundamental valuation.

RGNX+0.40

No priced-in read yet